Kaleido Bio CEO Lawton Resigns; Company Plans Search for Successor

Kaleido Biosciences (NASDAQ: [[ticker:KLDO]]) president and CEO Alison Lawton stepped down on Tuesday to “attend to an unexpected family health matter,” the microbiome therapies developer said. Lawton joined Kaledio in December 2017 as president and chief operating officer. She was promoted to chief executive in August 2018.

The Lexington, MA-based biotech, a Flagship Pioneering spinout, said Lawton plans to return to the UK, but that she will serve as a director and special advisor as Kaleido searches for a new CEO. In the meantime the company has established an “office of the CEO,” comprised of Lawton and the CEO she succeeded, Mike Bonney.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.